Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biological Potency of Peanut Allergen Extract (DBV712) in Peanut Allergy
NCT03352726Phase 1Completed
- Sponsor
- DBV Technologies
- Start
- Nov 2017
- Primary completion
- Jun 2018
- Modality
- Transdermal Patches
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DBV712 Viaskin® in peanut allergy, sponsored by DBV Technologies. Primary endpoint: Biological potency of the In-House Reference peanut proteins extract at 2 weeks. Started Nov 2017; status: completed.
02
Drugs
DBV712 Viaskin®
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT03352726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03352726.